Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 105 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nasal Polyposis Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT05274750
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 22, 2026, 10:05 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps

NCT02285283
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Itraconazole, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)

NCT03358329
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyposis
Interventions
S8 Sinus Implant
Combination Product
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Sacramento, California • New Haven, Connecticut • Naperville, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 22, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

NCT06850805
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
OPN-375, Placebo
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

Comparison of Nasal Steroids After FESS in CRSwNP

NCT02194062
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
fluticasone nasal spray, Budesonide head upright, Budesonide head forward
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
New Haven, Connecticut • Stratford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

NCT01624662
View directory record Official record
Conditions
Bilateral Nasal Polyposis
Interventions
Fluticasone propionate
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Stockton, California • Centennial, Colorado • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 22, 2026, 10:05 AM EDT
Not yet recruiting Not applicable Interventional

Active vs. Passive VR During Office-based ENT Procedures

NCT07599826
View directory record Official record
Conditions
Pain, Anxiety, Chronic Rhinosinusitis (CRS), Nasal Obstruction, Nasal Polyp, Eustachian Tube Dysfunction, Dysphonia, Subglottic Stenosis (SGS)
Interventions
Passive virtual reality headset or goggles, Active virtual reality headset or goggles
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 10:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

NCT03747458
View directory record Official record
Conditions
Bilateral Nasal Polyposis
Interventions
OPN-375
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • Bakersfield, California • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 10:05 AM EDT
Recruiting Phase 4 Interventional

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

NCT05094570
View directory record Official record
Conditions
Nasal Polyps, Staphylococcus Aureus
Interventions
Dupilumab Prefilled Syringe
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 22, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 10:05 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335
View directory record Official record
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 22, 2026, 10:05 AM EDT
Withdrawn Phase 4 Interventional

Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT02119273
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease

NCT00215787
View directory record Official record
Conditions
Nasal Polyps, Gastroesophageal Reflux
Interventions
lansoprazole
Drug
Lead sponsor
Head and Neck Surgery Associates
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Oct 22, 2026, 10:05 AM EDT
Withdrawn No phase listed Observational

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

NCT03369574
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Asthma, Nasal Polyps
Interventions
Reslizumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 22, 2026, 10:05 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Chronic Rhinosinusitis With or Without Nasal Polyps Steroid Study

NCT00841802
View directory record Official record
Conditions
Chronic Sinusitis, Rhinosinusitis, Nasal Polyps
Interventions
Prednisone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 22, 2026, 10:05 AM EDT
Terminated Phase 4 Interventional Results available

Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT01676415
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Prednisone, Topical mometasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 22, 2026, 10:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Tezepelumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Chicago, Illinois • Chestnut Hill, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

NCT01622569
View directory record Official record
Conditions
Bilateral Nasal Polyposis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

NCT03781804
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
OPN-375
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
46
States / cities
Gilbert, Arizona • Bakersfield, California • Folsom, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps

NCT02912468
View directory record Official record
Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Interventions
Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Long Beach, California • Orange, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis

NCT01197612
View directory record Official record
Conditions
Chronic Sinusitis, Polyposis
Interventions
pulmicort
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 22, 2026, 10:05 AM EDT
Completed No phase listed Observational

Role of Inflammatory Mediators in AERD

NCT02824523
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
aspirin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 22, 2026, 10:05 AM EDT
Recruiting Phase 4 Interventional

Biologics in Chronic Rhinosinusitis With Nasal Polyposis

NCT06824649
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyps
Interventions
Biologic Agents
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Gainesville, Florida • Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 10:05 AM EDT